1Ebollng PR,Work JD.Yeung S.et al.Effects of calcitriol or calcium on bone mineral density,bone turnover,and fractures in men with primary osteoporoeis:a two-year randomized double blind,double placebo study.J Cliu Endocrinol Metab 2001;86(9):4098—103. 被引量:1
2Gallagbor JC, Fowler SE, Detter JR, et al. Combination treatment with estrogen and calcltriol in the prevention of age-related bone loss. J Clin Endocrinol,Metab 2001; 86(8): 3618 -28. 被引量:1
3Sickels JM, Nip CS. Risedronate for the prevention of fractures in postmenopausal osteoporosis. Ann Pharmacother 2002; 36 (4) : 664 - 70. 被引量:1
4Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001; 38 (Pt 6) : 608 - 23. 被引量:1
5Neer RM, Arnaud CD, Zanchetta JR, et aL Effect of parathyroid hormone (1 -34) on fractures and bone mineral density in postmenopausal women with osteopomsis. N Engl J Med 2001 ; 344:1434 - 41. 被引量:1
6Binge JD, Rovati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.Calcif Tissue Int 2001; 69(4): 252-5. 被引量:1
7Rubin CD, Pak CY. Adams-Huet B. et al. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosls. Arch Intern Med 2001 ;161(19):2325 -33. 被引量:1
8Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reduc-tase inhibitors and the risk of hip fractures in elderly per-sons. JAMA 2000; 283:3211 -6. 被引量:1
7Marcus R.Post-menopausal osteoporosis[J].Best Pract Res Clin Obste Gynaecol,2002,16(3):309-327. 被引量:1
8Raisz LG.Pathogenesis of osteoporosis:concepts,conflicts and prospects[J].Clin Invest,2005,115(12):3318-3325. 被引量:1
9Umland EM,Rinaldi C,Parks SM,et al.The impact of estrogen replacement therapy and raloxifene on osteoporosis,cardiovascular disease and gynecologic cancers[J].Ann Pharmacother,1999,33(12):1315-1328. 被引量:1
10Col NF,Eckman MH,Karas RH,et al.Patient specific decisions about hormone replacement therapy in postmenopausal women[J].JAMA,1997,277(14):1140-1147. 被引量:1